Human/Mouse Cyclin B1 Antibody

Detection of Human Cyclin B1 by Western Blot. Western blot shows lysates of U2OS human osteosarcoma cell line, K562 human chronic myelogenous leukemia cell line, HeLa human cervical epithelial carcinoma cell line, and Jurkat human acute T cell leukemia cell line. PVDF Membrane was probed with 0.2 µg/mL of Goat Anti-Human/Mouse Cyclin B1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6000) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Cyclin B1 at approximately 62 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Cyclin B1 in Human Lymphoma. Cyclin B1 was detected in immersion fixed paraffin-embedded sections of human lymphoma using Goat Anti-Human/Mouse Cyclin B1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6000) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counter-stained with hematoxylin (blue). Specific staining was localized to cytoplasm in lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Human Cyclin B1 by Simple Western^TM. Simple Western lane view shows lysates of HeLa human cervical epithelial carcinoma cell line and Jurkat human acute T cell leukemia cell line, loaded at 0.2 mg/mL. A specific band was detected for Cyclin B1 at approximately 67 kDa (as indicated) using 2 µg/mL of Goat Anti-Human/Mouse Cyclin B1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6000) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Mouse Cyclin B1 by Western Blot C3G inhibits the growth of B16-F10 cells in vivo. In situ tumor growth monitored via Xenogen IVIS imaging at different time points after implanting syngeneic B16-F10-luc tumors into male C57BL/6 mice (n = 10) either fed with control or C3G diet for 4 weeks. (A) Melanoma tumor growth was monitored in real-time via bioluminescent imaging of luciferase activity in live mice using the cryogenically cooled IVIS-imaging system from baseline to week 4 post implantation. (B) Graphical representation of tumor weight and tumor growth was monitored using Vernier calipers. (C) Photographic images of excised tumors were captured (n = 3). The largest tumor size in diameter is 2.0 cm. (D) Hematoxylin and eosin staining of tumor and capillaries are red (arrows). (E) Cleaved-caspase-3 was brownish in the cytoplasm (arrows) of the tumor and (F) Western blot analysis of caspase 3 and CCNB1 in C3G-treated mice tumors. (G), TUNEL staining to detect late apoptotic cells of the tumor (left panel) and C3G-treated mice tumors (Right panel). Late apoptotic cells had brownish nuclear regions (arrows). Differences with *p < 0.05, **p < 0.01, or ***p < 0.001 were considered statistically significant. Scale bar is 100 μm. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31696058), licensed under a CC-BY license. Not internally tested by R&D Systems.